Protocols can be accessed by clicking on the trials' names.
CYCAZAREM (cyclophosphamide versus azathioprine for remission in generalised vasculitis) was completed and published in The New England Journal of Medicine in 2003.
SOLUTION (anti-thymocyte globulin for refractory vasculitis) was completed and published in Kidney International in 2004.
NORAM (methotrexate versus cyclophosphamide for 'early systemic' disease) was completed and published in Arthritis & Rheumatism in 2005.
CHUSPAN (Churg-Strauss and polyarteritis nodosa) was completed in 2005. Its four different protocols included either Churg-Strauss syndrome or polyarteritis nodosa (PAN) plus microscopic polyangitis (MPA) both either with good and poor prognosis. The results of PAN/MPA with bad prognosis were published in Arthritis & Rheumatism in 2003.
MEPEX (methyl prednisolone or plasma exchange for severe renal vasculitis) was completed and published in the Journal of the American Society of Nephrology together with a parallel study on renal histology in 2007.
CYCLOPS (daily oral versus pulse cyclophosphamide for renal vasculitis) was published in the Annals of Internal Medicine in 2009.
ABAVAS was started in 2008 and had to be terminated in 2009 because of insufficient funding.
STAVE is a meta-analysis of the effect of different corticosteroid dosing regimens on relapses. The report is accepted for publication in Arthritis Care and Research.
RITUXVAS compared a rituximab based regimen with a standard cyclophophamide / azathioprine regimen in the treatment of active, 'generalised' ACNA associated vasculitis. It started in 2006 finishing with the last patient visit in 2009. The report was published in the New England Journal of Medicine in 2010.
IMPROVE (International Mycophenolate mofetil to Reduce Outbreaks of Vasculitides) compared mycophenolate mofetil with azathioprine for maintenance of remission in renal vasculitis. Inclusions were competed in 2004 and the last visit took place in 2008. The report was published in the Journal of the American Medical Association JAMA in 2010.